International Stem Cell Corp (ISCO)
0.065
-0.01
(-8.71%)
USD |
OTCM |
Apr 24, 16:00
International Stem Cell Revenue (Quarterly): 1.889M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.889M |
| September 30, 2023 | 1.973M |
| June 30, 2023 | 1.841M |
| March 31, 2023 | 2.086M |
| December 31, 2022 | 2.43M |
| September 30, 2022 | 1.703M |
| June 30, 2022 | 2.027M |
| March 31, 2022 | 2.02M |
| December 31, 2021 | 1.843M |
| September 30, 2021 | 1.842M |
| June 30, 2021 | 1.833M |
| March 31, 2021 | 1.658M |
| December 31, 2020 | 1.476M |
| September 30, 2020 | 1.481M |
| June 30, 2020 | 1.812M |
| March 31, 2020 | 2.36M |
| December 31, 2019 | 2.837M |
| September 30, 2019 | 2.096M |
| June 30, 2019 | 2.321M |
| March 31, 2019 | 2.218M |
| December 31, 2018 | 2.223M |
| September 30, 2018 | 3.195M |
| June 30, 2018 | 3.038M |
| March 31, 2018 | 2.633M |
| December 31, 2017 | 1.842M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.847M |
| June 30, 2017 | 1.762M |
| March 31, 2017 | 2.005M |
| December 31, 2016 | 1.69M |
| September 30, 2016 | 1.943M |
| June 30, 2016 | 1.916M |
| March 31, 2016 | 1.616M |
| December 31, 2015 | 1.978M |
| September 30, 2015 | 2.136M |
| June 30, 2015 | 1.815M |
| March 31, 2015 | 1.622M |
| December 31, 2014 | 1.817M |
| September 30, 2014 | 1.963M |
| June 30, 2014 | 1.588M |
| March 31, 2014 | 1.649M |
| December 31, 2013 | 1.735M |
| September 30, 2013 | 1.67M |
| June 30, 2013 | 1.457M |
| March 31, 2013 | 1.285M |
| December 31, 2012 | 1.247M |
| September 30, 2012 | 1.187M |
| June 30, 2012 | 1.056M |
| March 31, 2012 | 1.077M |
| December 31, 2011 | 1.061M |
| September 30, 2011 | 0.842M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.476M
Minimum
Dec 2020
2.837M
Maximum
Dec 2019
1.975M
Average
1.889M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.065M |
| Perspective Therapeutics Inc | -5.239M |
| Protalix BioTherapeutics Inc | 10.49M |
| Electromed Inc | 13.69M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.458M |
| Total Expenses (Quarterly) | 2.313M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | 2.394M |
| Gross Profit Margin (Quarterly) | 54.31% |
| Profit Margin (Quarterly) | -24.25% |
| Earnings Yield | -52.69% |
| Normalized Earnings Yield | -52.69 |